Literature DB >> 8262630

Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall.

R G Keller1, G S Pfrommer, T R Kozel.   

Abstract

Previous studies found that normal human serum (NHS) contains an immunoglobulin G (IgG) antibody that mediates initiation of the classical complement pathway by nonencapsulated Cryptococcus neoformans. The present study used an enzyme-linked immunosorbent assay with whole nonencapsulated yeast cells as solid-phase antigens to demonstrate the presence of high levels of IgG antibody in each of 11 sera from normal adult donors. The IgG antibodies were of the IgG2 subclass. The antibody activity was blocked completely by treatment of serum with isolated yeast glucan. Treatment of serum with mannan or chitin had no effect on antibody levels. Antibody activity was adsorbed completely by treatment of serum with zymosan particles. Adsorption with intact cells of Saccharomyces cerevisiae or Candida albicans had no effect, suggesting that the glucan on S. cerevisiae or C. albicans is not surface exposed. Assessment of the opsonic requirements for phagocytosis of nonencapsulated cryptococci by monocyte-derived human macrophages (MO-M phi) showed that high levels of phagocytosis occurred when yeast cells were opsonized with NHS. Removal of anti-glucan antibody by adsorption with whole nonencapsulated cryptococci did not diminish opsonic activity. Heat-inactivated serum or anti-glucan antibody affinity purified from NHS lacked opsonic activity. Taken together, these results indicate that phagocytosis of nonencapsulated cryptococci by monocyte-derived human macrophages has an obligatory requirement for opsonic ligands of the complement system, with no contribution by the anti-glucan IgG that is found in NHS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8262630      PMCID: PMC186089          DOI: 10.1128/iai.62.1.215-220.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  EVIDENCE FOR IMMUNOLOGICAL SPECIFICITY OF THE PROPERDIN SYSTEM; DEMONSTRATION, ISOLATION AND PROPERTIES OF A SERUM FACTOR WHICH INTERACTS WITH ZYMOSAN AND OTHER POLYSACCHARIDES AT 0 DEGREES CENTIGRADE.

Authors:  L BLUM
Journal:  J Immunol       Date:  1964-01       Impact factor: 5.422

2.  On the composition of zymosan.

Authors:  F J DI CARLO; J V FIORE
Journal:  Science       Date:  1958-04-04       Impact factor: 47.728

3.  Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.

Authors:  M A Wilson; T R Kozel
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

4.  Cell-wall glucans of Cryptococcus neoformans Cap 67.

Authors:  P G James; R Cherniak; R G Jones; C A Stortz; E Reiss
Journal:  Carbohydr Res       Date:  1990-04-02       Impact factor: 2.104

5.  Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces.

Authors:  S K Law; N A Lichtenberg; R P Levine
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

6.  Ultrastructure of the cell wall of Candida albicans blastospores: study of its constitutive layers by the use of a cytochemical technique revealing polysaccharides.

Authors:  D Poulain; G Tronchin; J F Dubremetz; J Biguet
Journal:  Ann Microbiol (Paris)       Date:  1978 Feb-Mar

7.  The structure of a beta-(1 leads to 3)-D-glucan from yeast cell walls.

Authors:  D J Manners; A J Masson; J C Patterson
Journal:  Biochem J       Date:  1973-09       Impact factor: 3.857

8.  The glucan components of the cell wall of baker's yeast (Saccharomyces cerevisiae) considered in relation to its ultrastructure.

Authors:  J S Bacon; V C Farmer; D Jones; I F Taylor
Journal:  Biochem J       Date:  1969-09       Impact factor: 3.857

9.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

10.  Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.

Authors:  T R Kozel; M A Wilson; J W Murphy
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more
  22 in total

1.  Antibody response to Cryptococcus neoformans proteins in rodents and humans.

Authors:  L C Chen; D L Goldman; T L Doering; L a Pirofski; A Casadevall
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

3.  Proteins in the cell wall and membrane of Cryptococcus neoformans stimulate lymphocytes from both adults and fetal cord blood to proliferate.

Authors:  C H Mody; K L Sims; C J Wood; R M Syme; J C Spurrell; M M Sexton
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

4.  An opsonizing monoclonal antibody that recognizes a noncapsular epitope expressed on Cryptococcus neoformans.

Authors:  G J Merkel; B A Scofield
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

5.  Influence of mannan and glucan on complement activation and C3 binding by Candida albicans.

Authors:  Gayle M Boxx; Thomas R Kozel; Casey T Nishiya; Mason X Zhang
Journal:  Infect Immun       Date:  2009-12-22       Impact factor: 3.441

Review 6.  Host immunity to Cryptococcus neoformans.

Authors:  Soma Rohatgi; Liise-Anne Pirofski
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

7.  Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.

Authors:  A Vecchiarelli; C Retini; A Casadevall; C Monari; D Pietrella; T R Kozel
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.

Authors:  Carla Bromuro; Antonella Torosantucci; Paola Chiani; Stefania Conti; Luciano Polonelli; Antonio Cassone
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Circulating beta (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis.

Authors:  N Kondori; L Edebo; I Mattsby-Baltzer
Journal:  Clin Diagn Lab Immunol       Date:  2004-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.